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ADHEREN CE: 
 
The terms compliance and adherence are used to express the concept of 
matching the patient behavior, attitude and actions in conformity with the suggestions,  
expectation or intensions of the treating  physician.  It is an action or process initiated  
and  complete  in accordance with a request, command, direction or instruction. The 
extent to which the patients do  this  is expressed  by the  term patient compliance  
which  is an old  term,  widely  used throughout the world. Other newer terms like 
“patient adherence”, medication adherences were recommended in place of patient 
compliance in the recent past.  Adherence to oral pharmacologic therapy is a complex 
and multi factorial issue that can substantially alter the outcome of therapy.1. 
 
Adherence has recently been defined by the international society for 
pharmacoeconomics and outcome research as the extent to which a patient acts in 
accordance with the prescribed interval and dose of a drug regimen. A patient is 
optimally adherent if no doses are missed, no extra doses are taken and no doses are 
taken in the wrong quantity or at the wrong time. Adherence is measured over a 
period of time and reported as the adherent rate, which is the percentage of dose taken 
in relation to what was prescribed. The present concept of adherent in its real sense 
envisages issues related to diet,  lifestyle, exercise, rest, etc in addition to the use of 
medicines. However in pharmacy practice, patient adherence is seen  frequently  
discussed  from  the  point  of  view  of drug  therapy  only.  It  is  of  great 
importance in the determination of therapeutic outcome. How patient take their 
medication is a crucial component of whether they will respond as expected.2,3 
 
Measurement of adherence: 4,5 
 
There is no current golden standard measurement and all methods have 
limitations. The major limitation of measuring adherence is the so-called  Hawthorne 
effect,  i.e.  the monitoring of adherence  itself  influences adherence; because the 
awareness of patient that adherence is being monitored may influence their behavior. 
Adherence rates for many chronic drug therapies range between 35% and 70%. The 
consequences of poor adherence are poor health outcome and increased health care 
cost. Proper diagnosis of the disease is essential for planning effective treatment.     
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Similarly detection of non adherence is an essential prerequisite for making the 
treatment effective. Like certain diseases, patient adherence or non adherence is a 
changing behavior and hence necessitates continuous monitoring. Apart from the on 
the spot observance and recording at the time of medication taking or treatment 
implementation, there is no specific or ideal method available to evaluate or detect 
patient compliance. Direct on the spot observation of the patient is not an always a 
practical method and hence many methods were suggested, though not ideal or 
perfect. 
 
Current detection method of adherence includes direct methods and indirect 
methods. All these  methods have their own limitations. None is fully dependable. 
Some rely on the honesty,  integrity  and  dependability  of the  patient  others  are  
intrusive  and  are  of only experimental  values.  The  direct  methods  are  believed  
to  have  a  higher  sensitivity  and dependability compared to the indirect methods.1 
 
DIRECT METHODS :6,7,8 
 
 The common direct methods to detect adherence are:- 
1. Direct observation 
2. Use of biological markers 
3. Tracer compounds and assay of body fluids 
 
Direct observation: Medicine adminis tration in homes and in hospitals could 
observe directly to confirm that the patient actually takes the medicine. Direct 
observation will help the patient to develop the skills to complain within certain cases 
like application of eye drops, and inhaler devices. 
 
Measurements of blood levels of marker: biological marker and tracer 
compounds in small amounts are added to the medicines and given to the patient. 
Then the level of marker in the body is measured. This will indicate patient  
adherence. S mall  amounts  of  tracer compounds with long half lives like low dose 
Phenobarbital are added to certain medicines and   measured   in  biological  fluids  as  
pharmacological   indicators  of  adherence.  With knowledge of drug kinetics, an 
estimate of dosing can be done. It can g ive both quantitative and qualitative data. 
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There are many problems with this method. There is an ethical issue in this type 
analysis, both regarding safety and necessity. Moreover an invasion is needed to 
obtain samples for analysis.9,10 
 
 Measurement of blood or urine levels of drug: Determination of drug 
concentration in the patient's biological fluids will also help to measure the adherence. 
In the case of drugs like digoxin or phenytoin analysis of blood plasma will help to 
detect their presence. The drug concentration in the body fluid will not help to provide 
data regarding timing of medicines used. 
 
INDIRECT METHODS; 11,12 
 
 The currently available indirect methods include: 
1)  Self report and direct interview 
2)  Pill and container counts 
3)  Achievements of treatment goals 
4)  Mechanical and electronic devices 
 
Self  report  and  interview: self  report  by  the  patient  and  their  interviews  
by  the pharmacist are the simplest and widely used methods to measure or detect 
adherence. Studies have shown that even the most skilled and scientific interviewing 
often fails to estimate the adherence. Self report and interview have the limitation that 
they are predominantly subjective methods of evaluation. Some patients may 
deliberately indicate a poor level of adherence. The use of diaries by patients could 
help for prospective reporting and can give more information if done properly. It is 
difficult to sustain dairy keeping for long periods. 
 
Pill and container counts: Counting of tablets, capsules etc,  is a method 
originally introduced in clinical drug studies to measure adherence. It is based on the 
presumption that a patient's adherence with the  medication  regimen can be estimated  
based  on counting  of residual pills in the original container given to him. The 
advantage of th is method is that, it can be done even at home by a relative or friend 
of the patient. If it is done on a regular basis, the number or quantity of the items used 
during a particular period can be found and that can indicate the adherence. However, 
pill dumping is common practice in certain categories of patients. P ill dumping is the 
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discarding of the medicines  in waste bins,  wash basins and toilets, etc., by patients to 
misrepresent their adherence to health care professionals and family members. 
 
Achievements of treatment goals: The theory of medicine teaches us that if a 
drug is administered  correctly,  there  should  be  an  observable  outcome,  an  
improvement  in  the condition of the patient. On certain occasions the achievement of 
treatment goals has been used  as a measure of patient's  adherence.  Here the health 
outcome measures are used as indicators of adherence.  But in certain cases like 
treatment of hypertension, diabetes,  etc, patients may load upon medication just 
before their visit to hospital or doctor. This will help them to have a normal blood 
pressure or blood sugar at the time of investigation or checking, but the patient was 
not following the regime properly. This type of behavior is called “Tooth brush 
effect” and can invalidate the health outcome strategy either partly or totally. 
 
Mechanical and electronic devices: Mechanical devices are first introduced in 
the eye drops where a chip was built in to  its cap. The chip helps to record each 
inversion of the bottle, and is taken to indicate use. But the disadvantage is that even a 
deliberate or accidental turn will be counted. 
 
NON- ADHEREN CE: 13,14 
 
If a patient not taking the medicines as recommended or not following the 
treatment schedule as  suggested by the physician,  he can be considered as non- 
adherent. Failure to follow and obey the  instructions regarding healthcare including 
diet regimen, exercise and other  lifestyle  activities  like smoking  or drinking  habits  
will also  constitute  for the  non adherence. Non adherence includes poor adherence 
and defective adherence. 
 
CAUSES OF NON ADHEREN CE: 1,15,16 
 
Drugs don't work  if people don't  take  them.  Medication  is  recommended  
to  the patients to  improve their health or cure their diseases.  Available data shows 
that a large percentage of patients, for a  variety of reasons, do not take their 
medications in the manner suggested,  creating  the  problem of non  adherence.  It  is  
true  that  some patients  make a conscious  decision  to  deviate  from  the  prescribed  
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regimen  (intentional  non-adherence). Adherence is sometimes  analyzed  as  
attitudinal  adherence  and   behavioral  adherence. Sometimes the attitude and 
behavior of the patient may be incongruent. Patients may sincerely intend to their 
medicines exactly according to the instructions, but fail because they forgot or failed 
to  understand the instructions. Different factors are responsible for non adherence. It 
may vary from patient to patient. Sometimes the patient may not like to take the 
medicines or may take not as directed but as per the decision of the patient himself. 
 
Why patients become non adherent? : lack of belief in the treatment, 
complexity of the disease, multiple  ailments,   inability  to  pay  for  the  medication,  
lack of awareness or information, multiple drug regimen, in convenient dosage times, 
administration difficulties, side effects, deliberate deviation from therapies due to 
factors like asymptomatic condition, symptomatic feelings of well being, fear of 
addiction or development of a new disease, etc, are some of the common reasons for 
non adherence. 
 
 Non adherence can lead to therapeutic failure, which in some cases results in 
serious complications or death. If an epileptic patient fails to take medicines there is 
every chance for the recurrence of epilepsy. 
 
GENERAL FACTORS OF NON ADHERENCE:1,17,18 
 
Numerous  factors of various types can be suggested  to  contribute to  patient  
non- adherence. Some of the more important and commonly considered factors are 
noted below. 
1. Type of disease or illness: The nature or type of illness can sometimes contribute 
to non adherence. Psychiatric patients may not have the ability to cooperate with 
the treatment.   Mentally   disturbed   patients   may   find   adherence  difficult.   P 
hysical disabilities can make swallowing difficult if a tablet is too large. When the 
patients are asymptomatic  or  symptoms subside,  it  is difficult  to  convince  the 
patient of the importance of drug therapy, if a patient feels better after taking the 
medicine he may also feel that he no longer needs to take, once the symptoms 
subside. 
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2. Physical limitations: many physical factors can affect the adherence. In certain 
cases distance can be a factor. The patient may have to travel a long distance to 
procure the medicine. Physical dexterity is required for the administration of some 
medicines as in the case of eye drops. The patient has to tilt  his head, squeeze on 
a small bottle and aim accurately a small distance from the eye in order to 
successfully instill a drop in to the  eye.  Certain  patients  may  find  it  difficult  
or  impossible.  Dosage  forms  like suppositories,  pessaries,  rectal creams,  
buccal tablets,  etc.,  also  require  skills  for proper administration.  Very small 
tablets may cause handling problems for certain patients. Dysphagia, a difficulty 
in swallowing, is often a problem for many. 
3. Therapeutic  regimen: A drug regimen  includes the  dose,  dosage  form,  route 
and frequency of administration, and duration of the therapy. It is often found that 
the more complex the therapeutic regimen, the less will be the adherence. The 
degree of non  adherence  is  directly  related  to  the  complexity  of  the  
therapeutic  regimen. Complex   drug   regimen, multiple   drug   therapy   
(polypharmacy)   and frequent administration of medication naturally attract non 
adherence. 
a) Multiple drug therapy: As the number of medicines a patient has to take 
increases, the risk of non adherence also increases in direct proportion. 
b) Frequency and duration of dosing: The increase in frequency of 
administration of medication leads to non adherence due to various reasons 
like forgetting to take or inconvenience to take at the same time. It is always 
advisable to select medications that permit the lowest daily prescribed dose 
frequency for improving adherence. 
c) Adverse  effects: When patients experience symptoms, which  they attribute  
to adverse  effects  of  the  medicine, then  unless  they  can  be  persuaded that 
the potential benefits of treatment outweigh the disadvantages, they will stop 
taking the medicines. 
d) Cost of medication: Cost of the  medication  is a  factor  for  adherence  or  
non adherence in many cases. In the case of costly items the adherence is more 
if the patient has purchased the  items. In many cases, the patient may not be 
able to purchase costly items as they find them unaffordable. There are many 
reports of patients asking the pharmacist which is the more  important item. 
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Sometimes the price factor will compel the patients to introduce “rationing” 
for their medicines. 
e) Taste of medication: The taste of the medication becomes a problem mainly 
with pediatric oral  liquid  preparations. Geriatric patients  also  behave  in  a  
similar manner towards the taste of medications. More un palatable the dose, 
more are the chances of it being  missed  or  discontinued  as soon as there are 
any signs of improvements. 
f) Administration  of  medication: Administration  problems  arise  due  to  
incorrect measurement or use of in appropriate devices.  Some patients  may  
fail to  use metered dose  inhalations (MDI) properly and could result in 
adequate control of the  disease  condition  (e.g. asthma). Patients should  be  
advised  about  the techniques for administering medications to infants and 
young children as well as the use of oral dosing devices like the metered dose 
aerosol inhalation device. 
4. Religious beliefs: Religious beliefs can also affect adherence. It is mainly due to 
the materials used in the medicines. Alcohols, porcine insulin, gelatin capsules, 
shark liver oil, etc., are examples of items that were avoided by certain religious 
people. People of some cultures associate diseases with spiritual causes and not 
see the relevance of medicines. 
5. Social and psychological factors: the level of confidence a patient has in his 
doctor, is an important  factor in adherence. If the confidence is less, the chances 
of adherence with doctors direction is less, as the patient doubt the effectiveness. 
If the confidence level is very high, patient may tend  to over comply. Certain 
patients may develop confidence  in certain  medicines based  on their own 
experience or  from others or publicity (advertisement). People may see medicines 
in different ways, some will see them  highly  useful and  needy,  and  others  
consider  them as  dangerous,  risky or  poisonous items.19,20,21 
 
PATIENT EDUCATION: 22 
 
The OIG report in US (OIG, 1990), and the Nuffield report in UK, had 
recommended patient  education as the best way to  improve adherence. Many factors 
may influence the effectiveness of educational efforts and the development of 
adherence in patients. When the information is very precise or too detailed, or the 
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patient may not understand or comprehend it. Complex terms and unnecessary jargons 
should be avoided. 
 
ADHEREN CE AIDS : 23 
 
 The patient adherence can be reinforced  considerably with the  help  of 
various aids including; 
 Labeling:  the  labeling  of  the  dispensed  items  should  be  accurate  and  
specific. Auxiliary labels providing additional information regarding the use, 
precautions and storage will contribute to patient adherence. 
 Medication calendars and drug reminder charts. 
 Special medication containers: 28-  compartment  “Mediset” container  and  
“Dosett “dispensing device (manufactured by Apothecary products, inc. and 
Astra pharmaceuticals respectively) are examples of special medications 
containers. This device contains 4 compartments for different time periods 
(e.g. morning, afternoon, evening, bedtime) for each day of the week. 
 Adherence packing: It is defined as a prepackaged unit that provides one 
treatment cycle of the medication to the patient in a ready to use package. 
 Leaflets: The  most satisfactory of the  leaflets  is the patient package  insert  
(PPI), supplied  with  unit  pack  items.  They  should  contain  clear  
instructions  in  simple language and clear illustrations. 
 Posters: Additional  information can be provided  by posters,  pictures and  
warning cards. 
 
CANCER 24,25,29 
 
The body is made up of trillions of living cells. Normal body cells grow, 
divide, and die in an orderly way. During the early years of a person's life, normal 
cells divide faster to allow the person to grow. After the person becomes an adult, 
most cells divide only to replace worn out, damaged or dying cells. 
 
Cancer begins when cells in a part of the body start to grow out of control. 
There are many kinds of cancer, but they all are start because of this out of control 
growth of abnormal cells. Cancer cell growth is different from normal cell growth.  
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Instead of dying, cancer cells keep on growing and form new cancer cells. These 
cancer cells can grow in to (invade) other tissues, something that normal cells cannot 
do. Being able to grow out of control and invade other tissues is what makes a cell 
cancer cells. 
 
THE CELL CYCLE:44 
 Cell proliferation is involved in many physiological and pathological 
processes including growth, healing, repair, hypertrophy, hyperplasia and the 
development of tumours. Angiogenesis (the development of new blood vessels) 
necessarily occurs during many of these processes.  
 
 Proliferating cells go through what is termed the cell cycle, during which the 
cell replicates all its components and then bisects itself into two identical daughter 
cells. Important components of the signalling pathways in proliferating cells are 
receptor tyrosine kinases or receptor-linked kinases, and the mitogen-activated kinase 
cascade. In all cases, the pathways eventually lead to transcription of the genes that 
control the cell cycle. 
 
Figure showing cell division 
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All cells display a similar pattern during the cell division process, although 
differences in the duration of the cell cycle occur between cells of various types: 
 
 The cell cycle is an ordered series of events consisting of several sequential 
phases: G1, S, G2 and M. 
 M is the phase of mitosis. 
  S is the phase of DNA synthesis. 
  G1 is the gap between the mitosis that gave rise to the cell and the S phase; 
during G1, the cell is preparing for DNA synthesis. 
  G2 is the gap between S phase and the mitosis that will give rise to two 
daughter cells; during G2, the cell is preparing for the mitotic division into two 
daughter cells.  
M Containing a double complement of DNA, divides in to two daughter 
cells. Each of these daughter cells may immediately re-enter the cell cycle or pass in 
to a non proliferative stage, referred to as G0. The G0   cells of certain specialized 
tissues may differentiate in to functional cells that no longer are capable of division.  
On the other hand, many cells,  especially  those  in slow- growing tumors, may 
remain in the state for prolonged periods, only to re-enter the division cycle at a later 
time. Each transition in the cell cycle is controlled by the activity of specific cyclin-
dependent kinases (CDKS),   which   are  activated  by  their  corresponding   small 
regulatory proteins called cyclins, and inhibited by proteins such as p16. Mutations or 
loss of p16 or other components of the so-called retinoblastoma pathway such as  
retinoblastoma protein itself, or enhanced cyclin or CDK activity, will lead to 
relentless proliferation in tumor cells.  Consequently, CDKS  and  their  effector  
proteins  have  become  attractive  molecular targets for new antineoplastic agents. 
 
In most cases the cancer cells form a tumor but some cancers like leukemia, 
rarely form tumors. Instead these cancer cells are in the blood and bone marrow. 
When cancer cells get into the blood stream or lymph vessels, they can travel to other 
parts of the body. There they begin to grow and form new tumors that replace normal 
tissues. This process is called metastasis. No matter where a cancer may spread, it is 
always named for the place where it started. For instance breast cancer that has spread 
to the liver is still called breast cancer not liver cancer. Likewise, prostate cancer that 
has spread to the bone is called metastatic prostate cancer not bone cancer.30 
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Not all tumors are cancerous. Tumors that aren't cancer are called “benign”. 
Benign tumors can cause problems they can grow very large and press on healthy 
organs and tissues. But they cannot grow in to other tissues because of this, they also 
can't sp read to other parts of the body (metastasize). These tumors are almost 
never life threatening. Malignant tumors are usually rapidly growing, invading 
surrounding tissue and,  most significantly, colonizing distant organs. The ability of 
tumor cells to detach from the original mass (the primary tumor) and  set up a  
metastasis (secondary tumor) discontinuous with the primary is unequivocal proof of 
malignancy.31 
 
Neoplasm   arises from   transformed   cells   by  a   process   known   as 
multistep carcinogenesis. The first step in this process is called initiation, which is a 
change in DNA that can be  induced by a variety of chemical, viral and physical 
agents. In most cases, the additional presence of a tumor-promoting agent  is  needed  
to  complete  the carcinogenic process. Individual susceptibility to  malignant 
transformation may be influenced by genetic factors. This can relate to abnormal 
DNA mechanisms, to the variable expression of cellular oncogenes  that appear to 
play a role in normal and abnormal cell differentiation, or to the loss of tumor 
suppressor genes. The subsequent growth of a transformed cell as a clone can lead to 
additional sub clones who have acquired genetic variability results in considerable 
tumor cell heterogeneity within any given tumor. Tumor cells may be less genetically 
stable than tumor cells- possibly from the activation or suppression of specific gene 
loci, the continued presence of carcinogens, the development  of abnormal DNA 
repair mechanisms, or even nutritional deficiencies within the tumor. The inherent 
genetic instability of these cells, accompanied by variable processes of cell loss and 
selection, can result in advanced  neoplasms with unique 
biologic and cytogenetic characteristics.32 
 
Neoplastic cells are quite similar to normal cells there for the drugs targeted to 
kill these cells can also kill normal cells. As most of these drugs are acting on rapidly 
dividing cells, the normal cells having quick turnover are most susceptible to toxicity. 
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STAGES OF CANCER:
46
 
 
Overall Stage Grouping is also referred to as Roman Numerals, Staging. This 
system uses numerals I, II, III, and IV (plus the 0) to describe the progression of 
cancer. 
 Stage 0: carcinoma insitu. 
 Stage I: cancers are localized to one part of the body. Stage I cancer can be 
surgically removed if small enough. 
 Stage II: cancers are locally advanced. Stage II cancer can be treated by 
chemo, radiation, or surgery. 
 Stage III: cancers are also locally advanced. Whether a cancer is designated 
as Stage II or Stage III can depend on the specific type of cancer; for example, 
in Hodgkins disease, Stage II indicates affected lymph nodes on only one side 
of the diaphragm, whereas Stage III indicates affected lymph nodes above and 
below the diaphragm. The specific criteria for Stages II and III therefore differ 
according to diagnosis. Stage III can be treated by chemo, radiation, or 
surgery. 
 Stage IV: cancers have often metastasized, or spread to other organs or 
throughout the body. Stage IV cancer can be treated by chemo, radiation, 
surgery. 
 
 There is a separate TNM system for each type of cancer. General descriptions 
of the TNM staging system are listed below.  
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T: The letter "T" plus a number (0 to 4) is used to describe the size and location of the 
tumor, including how far the tumor has grown into nearby tissues. A larger tumor 
or a tumor that has grown more deeply into the surrounding tissue is given a 
higher number. For some types of cancer, lowercase letters, such as “a,” “b” or 
"m" (multiple), are added to the “T” stage category to provide more detail. 
 
N: The letter "N" plus a number (0 to 3) describes whether cancer has been found in 
the lymph nodes, and, in some types of cancer, how many of these lymph nodes 
contain cancer. Lymph nodes are tiny, bean-shaped organs that help fight 
infection. Lymph nodes located closest to where the cancer began are called 
regional lymph nodes. Lymph nodes in other parts of the body are called distant 
lymph nodes. Most often, the more lymph nodes with cancer, the larger the 
number assigned. However, for some types of tumors, the location of the lymph 
nodes with cancer may determine the “N” stage category. 
 
M: The letter "M" indicates whether the cancer has metastasized (spread) to other 
parts of the body. If the cancer has not spread to other parts of the body it is said 
to be M0; if the cancer has spread to other parts of the body, it is considered M1. 
 
ANTICANCER DRUGS:
45
 
 
        The available anticancer drugs have distinct mechanisms of action which may 
vary in their effects on different types of normal and cancer cells. A single "cure" for 
cancer has proved elusive since there is not a single type of cancer but as many as 100 
different types of cancer. In addition, there are very few demonstrable biochemical 
differences between cancerous cells and normal cells. For this reason the effectiveness 
of many anticancer drugs is limited by their toxicity to normal rapidly growing cells 
in the intestinal and bone marrow areas. 
 
 Several classes of drugs may be used in cancer treatment, depending on the 
nature of the organ involved. For example, breast cancers are commonly stimulated 
by estrogens, and may be treated with drugs that inactivate the sex hormones. 
Similarly, prostate cancer may be treated with drugs that inactivate androgens, the 
male sex hormone. However, the majority of antineoplastic drugs act by interfering 
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with cell growth. Since cancerous cells grow more rapidly than other cells, the drugs 
target those cells that are in the process of reproducing themselves. As a result, 
antineoplastic drugs will commonly affect not only the cancerous cells, but others 
cells that commonly reproduce quickly, including hair follicles, ovaries and testes, 
and the blood-forming organs. 
 
 Antineoplastic drugs may be divided into two classes: cycle specific and non-
cycle specific. Cycle specific drugs act only at specific points of the cell's duplication 
cycle, such as anaphase or metaphase, while non-cycle specific drugs may act at any 
point in the cell cycle. In order to gain maximum effect, antineoplastic drugs are 
commonly used in combinations. 
 
PRECAUTIONS:
41
 
 
 Because antineoplastic agents do not target specific cell types, they have a 
number of common adverse side effects. Hair loss is common due to the effects on 
hair follicles, and anemia, immune system impairment, and clotting problems are 
caused by destruction of the blood-forming organs, leading to a reduction in the 
number of red cells, white cells, and platelets. Because of the frequency and severity 
of these side effects, it is common to administer chemotherapy in cycles, allowing 
time for recovery from the drug effects before administering the next dose. Doses are 
often calculated, not on the basis of weight, but rather based on blood counts, in order 
to avoid dangerous levels of anemia (red cell depletion), neutropenia (white cell 
deficiency), or thrombocytopenia (platelet deficiency.) 
 
 Appropriate steps should be taken to minimize side effects. These may include 
administration of antinauseant medications to reduce nausea and vomiting, 
maintaining fluid levels to reduce drug toxicity, particularly to the kidneys, or 
application of a scalp tourniquet to reduce blood flow to the scalp and minimize hair 
loss due to drug therapy. 
 
         Patients receiving chemotherapy also are at risk of infections due to reduced 
white blood counts. While prophylactic antibiotics may be useful, the health 
care professional should also be sure to use standard precautions, including gowns 
INTRODUCTION 
ULTRA COLLEGE OF PHARMACY, MADURAI  PAGE 15 
and gloves when appropriate. Patients should be alerted to avoid risks of viral 
contamination, and live virus immunizations are contraindicated until the patient has 
fully recovered from the effects of chemotherapy. Similarly, the patient should avoid 
contact with other people who have recently had live virus immunizations. 
Other precautions which should be emphasized are the risks to pregnant or nursing 
women. Because antineoplastic drugs are commonly harmful to the fetus, women of 
childbearing potential should be cautioned to use two effective methods of birth 
control while receiving cancer chemotherapy. This also applies if the woman's male 
partner is receiving chemotherapy. Breastfeeding should be avoided while the mother 
is being treated. 
 
 
 Chemotherapy drugs, are sometimes feared because of a patient's concern 
about toxic effects. Their role is to slow and hopefully halt the growth and spread of a 
cancer. There are three goals associated with the use of the most commonly-used 
anticancer agents.
45
 
 
1. Damage the DNA of the affected cancer cells. 
2. Inhibit the synthesis of new DNA strands to stop the cell from replicating, 
because the replication of the cell is what allows the tumor to grow. 
3. Stop mitosis or the actual splitting of the original cell into two new cells. 
Stopping mitosis stops cell division (replication) of the cancer and may 
ultimately halt the progression of the cancer. 
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Categories of Chemotherapy Drugs45 
 
 In general, chemotherapy agents can be divided into three main categories 
based on their mechanism of action. 
 Stop the synthesis of pre DNA molecule building blocks 
These agents work in a number of different ways. DNA building blocks are folic acid, 
heterocyclic bases, and nucleotides, which are made naturally within cells. All of 
these agents work to block some step in the formation of nucleotides or deoxy 
ribonucleotides (necessary for making DNA). When these steps are blocked, the 
nucleotides, which are the building blocks of DNA and RNA, cannot be synthesized. 
Thus the cells cannot replicate because they cannot make DNA without the 
nucleotides. Examples of drugs in this class include 1) methotrexate, 2) fluorouracil, 
3) hydroxyurea, and  4) mercaptopurine. 
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 Directly damage the DNA in the nucleus of the cell 
These agents chemically damage DNA and RNA. They disrupt replication of the 
DNA and either totally halt replication or cause the manufacture of nonsense DNA or 
RNA (i.e. the new DNA or RNA does not code for anything useful). Examples of 
drugs in this class include cisplatin  and antibiotics - daunorubicin, doxorubicin, and 
etoposide. 
 Effect the synthesis or breakdown of the mitotic spindles 
Mitotic spindles serve as molecular railroads with "North and South Poles" in the cell 
when a cell starts to divide itself into two new cells. These spindles are very important 
because they help to split the newly copied DNA such that a copy goes to each of the 
two new cells during cell division. These drugs disrupt the formation of these spindles 
and therefore interrupt cell division. Examples of drugs in this class of 8) miotic 
disrupters include: Vinblastine (Velban), Vincristine (Oncovin) and Pacitaxel (Taxol). 
Antineoplastic agents  are  drugs  which  are  used  in  the treatment of cancer or 
malignancy. These drugs either kill or modify the growth of cancer cells. 
 Anti cancer drugs may be divided in to (on the basis of stage of cell cycle at which 
these     acts) two groups-  cell cycle specific (CCS) and cell cycle non specific 
(CCNS). CCS drugs are effective when the cells are proliferating where as CCNS 
drugs are effective whether the cells  are  dividing  or  are  in  the  resting  phase.  Cell  
cycle  specific  drugs  are  etoposide, antimetabolites, bleomycin, vinca alkaloids, 
taxanes, and estramustine. Cell cycle non specific drugs are platinum compounds, 
alkylating agents, anthracyclins,  dactinomycin,  mitomycin, and camptothesins. 
 
The practice of cancer medicine has changed dramatically in the past four 
decades, as curative treatments have been identified for a number of previously fatal 
malignancies such as testicular cancer,  lymphomas, and leukemia. New drugs have 
entered clinical use for disease presentations that were previously eit her untreatable 
or amenable only to local therapies such as surgery and  irradiation. At present,  
adjuvant chemotherapy  routinely  follows  local treatment of breast, colorectal, and 
lung cancer, and chemotherapy is employed as part of a multimodal approach to the 
initial treatment of many other tumors, including locally advanced stages of head and 
neck, lung and esophageal cancer, soft tissue sarcomas, and pediatric solid tumors. At 
the same time, chemotherapic drugs have found expanded utility in non cancero us 
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diseases.  The  same  drugs  used  for  cytotoxic  antitumor  therapy  have  become  
important components  of immunosuppressive  regimens  for rheumatoid  arthritis 
(methotrexate and cyclophosphamide), organ  transplantation (methotrexate and  
azathioprine),  sickle  cell anemia (5- azacytadine and hydroxy urea), antiinfective  
chemotherapy (trimetrexate and leucovorin ), and psoriasis (methotrexate ).33 
 
In designing specific regimens for clinical use, a number of factors must be 
taken in to account. Drugs are most effective in combination, and may be synergestic 
because of their biochemical interactions. It is more effective to combine drugs that 
do not share common mechanisms of resistance and that do not overlap  in their major 
toxicities. Cyto toxic drugs should be used as close as possible to their maximum 
individual doses and should be given as frequently as possible to discourage tumor re-
growth and maximize the dose intensity, the dose given per unit time, a key perimeter 
in the success of chemotherapy. S ince the tumor cell population in patients with 
clinically detectable disease exceeds 1 g, or 10 9 cells, and since each cycle of therapy 
kills less than 99% of the cells, it is necessary to repeat treatments in multiple  cycles  
to  eradicate  the  tumor cells.  An understanding  of cell- cycle kinetics is essential for 
the proper use of antineoplastic agents. Many of the most effective cytotoxic agents 
act by damaging DNA. Their toxicity is greater during the S, or DNA synthetic, phase 
of the cell cycle, while others, such as the vinca alkaloids and taxanes, block the 
formation of a functional mitotic spindle in M  phase. These agents have activity 
against cells that pass through the most vulnerable phase of the cell cycle.  
Accordingly, human neoplasams that currently are most susceptible to 
chemotherapeutic measures are those with a high percentage of cells undergoing 
division. S imilarly, normal tissues that proliferate rapidly (bone marrow, hair 
follicles, and intestinal epithelium) are subject to damage by most cytotoxic drugs, 
which often limits their usefulness. Conversely, slowly growing tumors with a small 
growth fraction (for example, carcinomas of the colon or non small cell lung cancer) 
often are less responsive to cycle- specific drugs.34 
 
Traditionally, cancer drugs were discovered through large- scale testing of 
synthetic chemicals and  natural products against rapidly proliferating animal tumor 
systems, primarily murine  leukemias.  Most  of  the  agents  discovered  in  the  first  
two  decades  of  cancer chemotherapy interacted with DNA or its precursors, 
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inhibiting the synthesis of new genetic material or causing irrepairable damage to DN 
A itself. In recent years, the discovery of new agents has extended from the more 
conventional natura l products such as paclitaxel and semi synthetic agents such as 
etoposide, both which target the proliferative process, to entirely new fields of 
investigation. 
 
Chemotherapy: Is a cancer treatment that uses chemical agents to kill cancer 
cells. The chemicals have a specific toxic effect upon cancer cells. They either destroy 
them or prevent the malignant cells from multiplying. The chemotherapy drugs may 
also have the same effect on normal cells. Administration of the drugs requires close 
monitoring for toxicity levels and for the patient's to therapy. Traditionally, 
chemotherapy has been administered by intravenous infusion in an oncology inpatient 
units or clinic or physicians office. Over the past decade, however, self administration 
of oral chemotherapy has increased because of the availability of novel therapeutic 
agents.
35
 
 
With the development of oral anticancer agents,  patients  have  more  choices 
and improved  convenience with receiving treatment than before. Yet, this implies 
that patients have to assume greater responsibilities for their treatment, with regards to 
adherence and safe handling of their medications.   Numerous advantages to the use 
of oral chemotherapy have been described, including increased control and 
convenience for the patient, potential increase in the quality of life, sustained 
medication exposure, and potential reduction in travel costs and use of  health  care 
resources.  Despite these advantages,  it  is  imperative to  note  that multiple  factors  
associated  with  oral  chemotherapy  can  compromise  patient  safety  and contribute 
to medication   errors, contamination   and inadvertent exposure to other 
individuals.
30,36
 
 
Chemotherapy because of its relatively narrow therapeutic index is often 
associated with  a  greater  risk  of adverse  events  (AES) than  other  medications,  
and  when  used  in combination, may result in an even greater incidence of AES. in 
contrast to administration in the institutional setting, where the prescribed medication,  
dose,  regimen and  response to therapy are subject to several levels of assessments, 
patient or caregiver (defined as family members, friends who assist the patient) 
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administration of oral chemotherapy is more likely to be susceptible to errors, non 
adherence, and increased AE S as a result of lack of coordinated care. Although there 
are no publications comparing chemotherapy errors that occur with oral versus  
intravenous  administration, known issues with oral administration include incorrect 
dosing and limited monitoring, which can lead to under dosing or overdosing, serious 
toxicity, morbidity and mortality. In addition patient non adherence to oral  
chemotherapy is a significant problem, which is a less of concern with parenteral 
therapy given in an institutional setting under the supervision of health care 
professionals.
37,38
 
 
Accidental exposure to  oral chemotherapeutic agents can  occur  at  various 
stages during  handling  (i.e. transport, unpacking, storage,  handling,  administration 
and disposal). Thus guidelines for safe  and  appropriate  handling  across the  health 
care continuum  are imperative. 
 
The shift to treating cancer with oral agents challenges traditional attitudes 
towards cancer care and requires new concepts of organization of oncology services. 
One of the most important challenges is the education of patients and the question of 
patients' adherence to treatment instructions.
40
 The use of orally administered anti 
cancer therapy is likely to increase dramatically  in the  coming  years. Agents such  
as   tamoxifen,   prednisone,   and   oral cyclophosphamide  have  long been part of 
the  management of many  malignancies.  More recently   developed   oral   
chemotherapy formulations include fluorouracil derivatives, idarubicine, etoposide, 
vinorelbine, oral taxanes, and fludaribine. New oral drugs have shown promising 
early clinical trials (e.g. S TI- 571 for chronic myelogenous leukemia) and  many 
other  novel agents  are  administered  orally.  Oral agents also  have dominant  role  
in the evolving field of chemoprevention of malignancies, where oral administration 
may improve efficacy in some settings by facilitating chronic exposure to the 
drug.
5,13,28
 
 
Because oral counter parts of intravenous (I V), agents may have different side 
effects profiles, they may be better tolerated in some circumstances. Furthermore, as 
oncologists pay more attention to  patient  preferences and quality of life  issues in 
clinical care,  treatment options that enhance flexibility for patients are likely to be 
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used more often. Adherence to any interventions over long periods  is determined  
largely by the  individual perceptions of the risks, benefits and costs of the 
intervention. Costs in this sense include not only economic outcomes but also  the 
potential toxic effects of therapy.  The psychosocial implications of taking 
medication(s) on an ongoing basis and the logistic demands of such treatments must 
also be considered. Adherence rate for many long term drug therapies have been 
shown to be strikingly low, often no more than 40% - 50%. C linicians generally 
assume that patients are taking the drugs are prescribed and, if they discuss the topic 
with their patients at all, believe their  patients  when  they say  they are taking  their  
medications as prescribed.  Subjective estimates  of  adherence  by  physicians  and  
nurses  are  unreliable  for  assessing  patient's medication use, with clinicians often 
failing to detect markedly poor adherence to prescribed regimens. Even when health 
care providers are aware of potential non adherence problems, they have been found 
to be unable to predict correctly which patients will adhere to therapy. 
 
ADHERENCE IN ONCOLOGY:
5,26,27,38
 
 
Cancer  patients  are  generally  thought  to  have  higher  adherence  rates  
than  other patients because  they are highly motivated by the gravity of their disease.  
However, cancer patients appear  to  have similar  adherence rates to  those of patients  
with other diseases. Treatment  duration  plays  a  role  in  adherence  to  the regimen. 
When the medication is continued over a longer period of time, patient become less 
adherent.  The measurement of adherence with medication that is used in complex 
cyclic schedules with stop periods and many individual adjustments during treatment, 
as often occurs in oncology, is challenging, since this  is  more difficult than  the  
measurement of  medication used  on a regular daily bases.46 
 
Medical oncologists and  hematologists may not always consider the  issue  of 
adherence. As yet suboptimal adherence may prove to be the greatest barrier to the 
various newly introduced oral anti cancer agents. 
 
 This study is intended to prescribe patients behavior regarding adherence and 
safe handling of oral anti cancer drugs.  Few  published  studies  have  focused  on  
adherence to oral anti neoplastic  therapy,  impart  because  the vast  majority of 
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chemotherapy is delivered intravenously in physicians offices or hospitals. With the 
rise in availability and increasing use of oral anti cancer agents, concerns about 
adherence to prescribed regimen will become an increasingly important issue in 
oncology. 
 
 HAZARDOUS DRUGS
42,43
  include those used for cancer chemotherapy, 
antiviral drugs, hormones, some bioengineered drugs, and other miscellaneous drugs.  
 
Hazardous drugs are drugs that pose a potential health risk to health care 
workers who may be exposed during preparation or administration. Such drugs 
require special handling because of their inherent toxicities. While most drugs are 
hazardous because they are cytotoxic, drugs from other categories are potentially 
harmful. 
 
Table 1. Criteria for Defining Hazardous Drugs 
Drugs that meet one or more of the following criteria should be handled as 
hazardous: 
 Carcinogenicity 
 Teratogenicity or developmental toxicity 
 Reproductive toxicity 
 Organ toxicity at low doses 
 Genotoxicity 
 Structure or toxicity similar to drugs classified as hazardous using the 
above criteria 
From Preventing Occupational Exposures To Antineoplastic And Other 
Hazardous Drugs In Healthcare Settings. (NIOSH, 2004) 
 
Many hazardous drugs used to treat cancer bind to or damage DNA (for 
example, alkylating agents). Other antineoplastic drugs, some antivirals, antibiotics, 
and bioengineered drugs interfere with cell growth or proliferation, or with DNA 
synthesis. 
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For example, antineoplastic drugs such as cyclophosphamide have 
immunosuppressant effects that proved beneficial for treating nonmalignant diseases 
such as rheumatoid arthritis and multiple sclerosis[Abel 2000]. 
 
All hazardous drugs, regardless of the formulation, should be labeled as such 
to prevent improper handling. Tablet and capsule forms of hazardous drugs should not 
be placed in automated counting machines, which subject them to stress and may 
introduce powdered contaminants into the work area. Counting and pouring of 
hazardous drugs should be done carefully, and clean equipment should be dedicated 
for use with these drugs. Crushing tablets or opening capsules should be avoided and 
liquid formulations should be used whenever possible. During the compounding of 
hazardous drugs (e.g., crushing, dissolving, or preparing a solution or an ointment), 
workers should wear non-permeable gowns and double gloves. Compounding should 
take place in a ventilated cabinet whenever possible [ASHP 2006]. 
 
 The main route of exposure to hazardous drugs was thought to be inhalation 
of drug aerosols generated during preparation. To reduce this risk, OSHA guidelines 
state that cytotoxic drug preparation must be performed in a biological safety cabinet 
(BSC) in a designated area, usually a pharmacy. A BSC has vertical airflow that 
moves away from the worker, as opposed to horizontal airflow that moves away from 
the product toward the worker. Vertical airflow protects the worker, while horizontal 
airflow is designed to protect the sterile product from contamination. Air leaving a 
BSC is filtered through a HEPA (high efficiency particulate air) filter. 
 
Table 2. Routes of Exposure to Hazardous Drugs 
 Inhalation of aerosolized drug 
 Dermal absorption 
 Ingestion 
 Injection 
  
Nurses who administer chemotherapy can be exposed to aerosols or droplets 
of drugs generated during administration. Body fluids of patients receiving hazardous 
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drugs are a potential source of exposure. Gloves and gowns are recommended to 
protect nurses against splash contamination during drug administration and handling 
patient wastes. 
 
Table 3. Personal Protective Equipment for Hazardous Drug Handling 
 Gowns – disposable, made of fabric that has low-permeability to the agents 
in use, with closed-front and cuffs, intended for single use. 
 Gloves – powder-free, labeled and tested for use with chemotherapy drugs, 
made of latex, nitrile, or neoprene. 
 Face and eye protection when splashing is possible. 
 A NIOSH-approved respirator when there is a risk of inhaling drug aerosols 
(such as spill clean up). 
(ASHP, 1990; Brown et. al, 2001; NIOSH, 2004; OSHA, 1996, OSHA, 1999) 
 
 "Procedures for proper handling and disposal of anticancer drugs should be 
considered. Several guidelines on this subject have been published. There is no 
general agreement that all of the procedures recommended in the guidelines are 
necessary or appropriate." 
 
 Hazardous drug handling is potentially risky work. Many nurses have the 
potential to be exposed to hazardous drugs in the workplace. OSHA, ASHP, ONS, 
and NIOSH all provide guidelines for the safe handling of hazardous drugs. While not 
providing complete protection, it is believed that adherence to current 
recommendations will reduce health care workers’ exposure. By reducing exposure, 
the negative health effects should be reduced. It is time for nurses to take their own 
occupational safety as seriously as the safety of the patients under their care. 
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1. Sim M.H,  Leaw Y.C and  Chan  A (2007) carried  out a study on safe 
handling of oral anticancer agents: perspectives from breast cancer patients at 
National cancer centre. Of the 126 surveys, 121 fit the inclusion criteria, of which 57 
are breast patients. Only 10% (17.5%) indicated that oral and parenteral anticancer 
agents are equally potent. Eight  (14%)  considered  their  oral anticancer  agents  to  
be  more  potent  than  the parenteral once. All disagreed or strongly disagreed that it 
was difficult to understand. Their regimen and 51 (89.5%) disagreed or strongly 
disagreed that it was difficult to adhere. 49 (86.0%) would dispose the bottles used to 
contain their oral anti cancer agents directly or indirectly down the chute and only 6 
(10.6%)  would  inform their healthcare  professionals  about  any  leftover  
medications  before  the  next  refill  or appointment. 36 
 
2. Lonneke Timme rs et al carried out study on ‘the use of capecitabine in daily 
practice ‘A study on adherence and patients experiences, in  the department of 
medical oncology, VU university medical centre, Amsterdam, the  Netherlands.  In 
this multicentre, prospective, observational cohort study, 90 patients aged 18 years or 
older starting treatment with capecitabine will be included and followed for a period 
up to five cycles. The main study  parameters  are  adherence,  patient  attitude  
towards medication, and the number and grade of patient reported sideeffects. The 
percentage of patients who are non adherent with drug therapy is estimated at 35%  
for patients with negative attitude towards capecitabine, and at 10% for patients with 
a positive attitude towards capecitabine. 27 
 
3. Veerle foulan et al. (2012) Studied of adherence to oral anticancer drugs (O 
AD) in patients with metastatic   renal   cancer (mRCC):  interim   results   of   the   p 
rospective, observational, multicentre, IPSOC study (investigating patients 
satisfaction with oral anti cancer treatment). The study was conducted at 11 Belgian 
hospitals between 02/2011 and 05/ 2012. 80 patients with a median age of 65 years 
have participated in the study. With a median follow up of 150 days (range 3-465)  
87% of patients claimed to be fully adherent (based on MMAS and C TSQ data) 10 
patients indicated to have missed at least one dose, for which the most important 
reasons were forgetting (38% of cases) and side effects (31 % ) based on MEMS r 
data, mean adherence, defined as the percentage of days with at least the prescribed  
number of dosage taken was 97.95%  interestingly, the prescribed regimen was 
changed or interrupted  by the treating oncologist in 36 % of cases. 22 
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4. Lucca et al. (2012) tested an educational intervention to enhance knowledge 
and adherence to Erlotinib while monitoring for side effects in 30 patients. Adherence 
behaviors were measured with the 8- items Morisky medication adherence scale 
(MMAS-8). MMAS - 8 adherence scores were median to high and the mean number 
of Erlotinib adverse event was 2.48 per patient. 22 % reported four or more side 
effects.5 
 
5. Anne S Oberguggenberger et al carried out the study on adherence 
evaluation of endocrine treatment in breast cancer: methodological aspects. It was 
carried out at the department of gynecology and obstetrics, medical university Inns 
bruck. The aim of the study was to compare four adherence measurement methods for 
their concordance in breast cancer patients undergoing anastrazole treatment. The 
result was found that the comparison of the four approaches using Spearman rank 
correlation revealed poor concordance across all methods reflecting weak correlations 
of 0.2-0.4. Considering this data incomparability across methods, they still observe 
high adherence rates of 78 -98% across measures.30 
 
6. Timme rs  et  al.  (2011) studied  an  ongoing  prospective  observational  
cohort  study  is examining  adherence ove r 16  weeks  for patients with  non small 
cell lung cancer. Adherence is measured  using MMAS -8, several questionnaires and 
plasma level of Erlotinib. F indings from this study will provide information about 
adherence and short term persistence to Erlotinib. 
 
 
7. Hess et al. (2012) examined adherence Sorafenib, S unitinib and Everolimus 
and found 81% had adherence rates of 80% or higher. Wolter et al. presented 
preliminary data of a prospective observational study measuring adherence using 
MEMS (medication events monitoring system). Adherence was 98.9%.33 
 
8. Gebbia et  al.  (2012) evaluated  the  impact  of  a  treatment-  monitoring  
intervention  on adherence for patients with advanced non small cell lung cancer 
receiving erlotinib as second  line  therapy  in  two  cohorts  1)  a  retrospective  non-  
interventional  phase monitoring  50  participants  without  a  treatment  management  
strategy  and  2)  a prospective interventional phase following 150 participants who 
received a treatment management program  including  identification  of a  caregiver,  
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patient  or  caregiver education and  training  about treatment  and  side effects of 
therapy,  a calendar  for following visit, and a dedicated fac smile phone line to 
receive instructions or use of a fast track visit system. Adherence was measured using 
multiple methods and generally patient self reported adherence was higher than 
adherence measured by pill counts. Disease control rate (complete response plus 
partial response plus stable disease was 44% in the first cohort and 63% in the second 
cohort (p=0.0368) also a significant correlation was found between the number of 
adverse events and adherence           (r= 0.176, p= 0.035).35 
 
9. Addeo  et  al.  (2011) conducted  a  study  on  adherence  to  lapanib  by  
using  self report, medication diaries and pharmacy controlled drug boxes. The study 
was carried out in 69 women and the adherence was 82%, with a 65% rate of dosing 
violations. 
 
10. Landier and Wandy et al carried out a study on predictions of non adherence 
to oral chemotherapy in children with acute lymphoblasts leukemia enrolled on 
children’s oncology group  study (AALL03N1) to  determine the prevalence of self/ 
parent reported  non adherence to  oral 6- mercaptopurine during the maintenance 
phase of A.L.L therapy. 22% of children in the cohort were non adherent to oral 
chemotherapy, defined as missing more than one dose of 6- mercaptopurine for non 
medical reasons over the 112 day observation period.  The risk of non adherence was  
significantly increased for those who failed to perceive the severity of the child’s 
illness.37 
 
11. Patridge et al. Conducted the study on adherence with capecitabine reported 
at The 2008 American society of clinical oncology annual meeting that 76% of 161 
breast cancer patients took at least 80% of their prescribed capecitabine doses, as 
measured by electronic monitoring system during a six cycle period. 14 
 
12. Winterhalder et al. Assessed adherence to capecitabine with self report in 
diaries. They observed that 91% of patients were adherent with all doses. 39 
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13. Smith et al. conducted the study of adherence in pediatric patients, used a 
urine assay for a 17- ketogenic steroid drug metabolite to differentiate between 
patients who taking prednisone as directed and those who were not, In 52 pediatric 
patients with leukemia or  non  Hodgkin’s  lymphoma,  33% of children overall  and  
59% of the adolescents were poorly  adherent, as defined by lower than expected  
levels of the urinary predmisone metabolite when sampled at random times. 40 
 
14. Wate rhouse et al. In a study of 26 patients with breast cancer, found that 
patients self report and  pill  count statistically significantly over estimated  the degree 
to which patients adhered to their tamoxifen regimen, as compared with data recorded 
by the MEMS device, in this study, patients were monitored for approximately 3 
months and classified as adherent if 80% or more of the tamoxifen doses were taken 
as prescribed. This rate was chosen as the cutoff because it is frequently cited in the  
literature as achievable  or  acceptable,  when  all dosing  errors as  measured  with 
MEMS  were considered, 18 of 24 patients  were non adherent, that is they took less 
than 80% of their doses as prescribed (including dose omissions and/ or schedule 
errors) during the  monitoring  period. If only dose  omissions  as  recorded  with  
MEMS  were considered,  patient  adherence rates ranged from 36.4% to 100% with 
an overall average of 85.4% (standard deviation+/17.2%).
5
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AIM: 
 In view of increased usage oral anti cancer drugs in the contemporary 
treatment of cancer, this study intended to describe patients’ experience and their 
adherence of oral anti cancer drugs by using a combination of multiple choice, scaled 
and open ended questions. For the purpose of this study, anti cancer  agents would  
include cytotoxics and  hormonal agents. 
 
OBJECTIVE: 
1) To investigate cancer patients’ adherence with their oral anticancer agents. 
2) To study the patients’ experience with their oral anticancer drugs, especially 
the behavior regarding handling and storage. 
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 The present dissertation work was planned to conduct A STUDY ON 
PATIENTS’ MEDICATION ADHERENCE AND PRACTICES WITH THEIR 
ORAL ANTICANCER AGENTS. The present study was planned to conduct in the 
outpatient Department of Oncology in Care Hospital, Hyderabad, Andhra Pradesh. 
 
i. Submission of the protocol for getting the approval from Ethical 
committee. 
ii. To get the consent letter from patients. 
iii. Select the cancer patients with inclusion and exclusion criteria for study. 
iv. To design a data collection form. 
v. Patient medication adherence is measured by standard medication 
adherence questionnaire. 
vi. Patients' behavior regarding safe handling and storage of medication has to 
determine. 
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STUD Y D ESIGN 
 
This is a single centre, cross sectional, interviewer administered study carried 
out at the outpatient oncology department and outpatient pharmacy of CARE 
Hospital, Hyderabad. This study was reviewed and approved by the Institutional 
Ethics Committee of Ultra College of Pharmacy.  Written and  signed  informed  
consent  was obtained  from all patients or caregivers prior to study entry. 
 
SUBJECTS 
 
Patients  had  received  at  least  one  cycle  of  oral  anti  cancer  agent  
treatment (chemotherapy)  or  had  been  taking  oral agents continuously  for  three  
months  (hormone therapy) are eligible for this study. Selected patients had a 
confirmed diagnosis of cancer and receiving at least one oral anti cancer agents. To be 
eligible for this study patients were able to read and understand English, be 25 years 
old and above as well as willing participate in the study. According to the sample size 
a minimum number of 120 patients are to be enrolled. 
 
Oral a ntica ncer age nts ava ilab le at CHH during stud y 
Pharmacologic class Oral anti cancer agents 
Alkylating agents Lomustine, cyclophosphamide, temozolomide 
Antimetabolites Azathiaprine, capecitabine, methotrexate, mercaptopurine 
Antihormonal agents Anastrazole, letrazole, flutamide, bicalutamide, tamoxifen 
Immuno modulator thalidomide 
Topoisomerase inhibitors Etoposide 
Thyrosine kinase inhibitors Erlotinib, gefitinib, imatinib 
Multikinase inhibitors Sorafenib, sunitinib 
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DATA COLLECTION AND ANALYS IS 
 
A standardized procedure was  adopted. The survey or  procedure consisted  of 
a combination of multiple choices, scaled and open ended questions. The content of 
the study or survey was divided in to two major areas. 
 1) Patients adherence to oral anti cancer drugs,  
 2) patients behavior towards handling of oral anti cancer drugs.  
 Most information is collected directly from patients or caregivers. The medical 
information is retrieved from the patients file. 
 
PATIEN T FILE: The following items are obtained from the patient treatment file 
o  Disease characteristics, including disease stage and treatment line. 
o  Dose of the medication and co medication. 
o   Patients characteristics i.e. age, gender etc. 
 
INTERVIEWS: 
 
The  interviews  were  carried  out  in  the  outpatient  department  of  
oncology  and outpatient pharmacy at oncology departments. The following variables 
were investigated: age, gender, educational status, smoking, and alcohol consumption, 
currently  prescribed  oral anticancer drugs, amount of medication, and type of cancer, 
stage of cancer and tobacco use. 
 
QUESTIONNAIRE 
 
Adherence was measured by using the 8 item Morisky medication adherence 
scale (MMAS-8).  The  MMAS-8, an  update with  greater sensitivity of the four item 
scale was published in 1986 and it is considered as the most commonly used self 
reporting method to determine adherence,  it contains eight  questions with closed 
dichotomous  (YES OR NO) answers, designed to prevent the bias of positive 
responses from patients questions asked by health  professionals,  by  reversing  the  
responses  related  to  the   interviewers'  medication adherence behavior. 
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Thus each question measured a specific adherence behavior. O ut of eight 
questions seven questions must be answered negatively and only one question 
positively, and the last question being answered according to a scale of five options : 
a) never or rarely, 
b) once in a while, 
c) sometimes,  
d) usually, 
e) all the time. 
 
      The degree of adherence was determined according to the score resulting from 
the sum of all the  correct  answers. If the score is 0 they will considered as following  
high adherence,  if it is 1 or   2  points average adherence, and > 2  points, considered 
as poor adherence. Patients’ attitude or action taken by the patient when they missed 
one dose is also checked. It is identified by using different sugges tions include skip 
missed doses, double up with the next dose, do not know, contact physician, resume 
taking the dose when remember. Another section this study discuss about the handling 
of drugs by the patients i.e. action take n after  picking up the dropped  medication, 
checking hand washing habits after handling oral anti cancer  agents,  how  they  store  
their  anti cancer  medication  i.e.  placed  with  other medication or placed separately. 
 
METHODOLGY 
STUDY DESIGN 
 
        A single centre, cross sectional, interviewer administered study. 
 
STUDY CENTRE 
 
         Outpatient department of Oncology, Care Hospitals, Hyderabad. 
 
STUDY POPULATION 
 
       Patients visiting the outpatient department of oncology, Care Hospitals, 
Hyderabad. 
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STUDY PERIOD 
       3 months  
                                                                                                                                         
SAMPLE SIZE 
        120 
 
STUDY ELIGIBILITY 
INCLUSION CRITERIA 
1) Patients of either sex aged  > 25 
2) Patients received atleast one cycle of oral anti-cancer agent treatment or had 
been taking oral anticancer agents continuously for 3 months. 
 
EXCLUSION CRITERIA 
1) Terminally ill patients 
2)  The use of oral anticancer drugs for non- oncological diseases 
 
METHODOLGY 
 
This is a single centre, cross sectional, interviewer – administered study going 
to conduct at the outpatient pharmacy of oncology department, Care Hospitals, 
Hyderabad. Patients’ receiving at least one cycle of oral anticancer agent or have been 
taking oral agents continuously for three months are eligible for the study.  
    
 Patient medication adherence is measured by interviewing patients with 
medication adherence questionnaire. It consists of combination of multiple choice , 
scaled and open ended questions. The content of the study is divided in to 2 major 
areas;  
1. Patients adherence to oral anticancer drugs,       
2. Patients behavior regarding storage and handling of oral anticancer drugs. 
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      A total of 126 patients' data were collected. Cancer patients receiving oral 
anticancer drugs were identified as eligible for inclusion in this study. A total of 126 
patients provided written informed consent. The majority of patients were on 
capecitabine (38.88%), tamoxifen (30.95%), gefitinib (8.73%), aromatase inhibitors 
(6.34%), thalidomide (3.96%), imatinib, etoposide (2.38%), temozolomide, 
bicalutamide, methotrexate, sorafenib(1.58%). The median age of studied population 
was 54 years old (25-84). 
 
PATIENTS DEMOGRAPHICS: 
1) GENDER OF THE PATIENT: 
 
TABLE NO:1 
 
Percentage Frequency(n) SEX 
44.44% 56 MALE 
55.55% 70 FEMALE 
n=126 
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GRAPHICAL REPRESENTATION OF DISTRIBUTION GENDER 
OF PATIENTS 
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2) AGE DISTRIBUTION OF PATIENTS: 
 
TABLE NO:2 
 
Percentage Frequency(n) Age  group 
3.97% 5 25-34 
12.7% 16 35-44 
27.8% 35 45-54 
33.3% 42 55-64 
21.4% 27 65-74 
0.08% 1 75-84 
 
 
The median age of the patients was about 60 years, with the majority of the 
patients falling in the range of 45 to 74 years old. 
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GRAPHICAL REPRESENTATION OF AGE DISTRIBUTION OF 
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3)  EDUCATIONAL LEVELS OF PATIENTS: 
 
TABLE NO:3 
 
 
Percentage 
 
Frequency(n) 
 
Education 
 
88.09% 
 
111 
 
School 
 
7.94% 
 
10 
 
Graduation 
 
0.79% 
 
1 
 
Post graduation 
 
31.17% 
 
4 
 
Illiterate 
                                                       N=126 
 
       Majority of the patients 111(88.09%) having only secondary school education or 
less, 10 (7.94%) of the patients were graduates, 1 (0.79%) and 4 (31.17%) are 
illiterate. 
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GRAPHICAL REPRESENTATION OF EDUCATIONAL LEVELS 
OF PATIENTS: 
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4) SOCIAL HABITS OF THE PATIENTS: 
 
TABLE NO:4 
 
Percentage Frequency(n) Habits 
27.7% 35 Alcoholics 
16.66% 21 Smoking 
3.17% 4 Tobacco use 
 
      Different studies have suggested that the social habits of the patient will be a 
contributing factor in the development of the disease. Here in this study 35 (27.7%) 
patients were alcoholics, 21 (16.66%) were smokers and the number of patients using 
tobacco are 4 (3.17%). 
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GRAPHICAL REPRESENTATION OF SOCIAL HABITS OF THE 
PATIENTS: 
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5) NUMBER OF COMORBIDITIES OF PATIENTS: 
 
TABLE NO:5 
 
Percentage Frequency(n) 
No. of co-    
morbidities 
46.82% 59 0 
29.3% 37 1 
18.25% 23 2 
5.55% 7 3 
 
        The comorbidities that were taken into consideration includes hypertension, 
diabetes, hypercholesterolemia, asthma. The majority of the patients 59 (46.82%) had 
none of the comorbidities, 37 (29.3%) had one of the comorbidities, 23 (18.25%) had 
two. A minority  of   7 (5.55%) had 3 comorbidities. 
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GRAPHICAL REPRESENTATION OF NUMBER OF 
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6) PRIMARY TUMOUR SITE: 
 
TABLE NO:6 
 
Percentage Frequency(n) Tumor site 
33.33% 42 Breast 
15.87% 20 Lung 
38.88% 49 Gastro intestinal 
2.38% 3 Liver 
0.79% 1 Kidney 
0.79% 1 Prostate 
6.34% 8 Multiple myeloma 
1.58% 2 Bone 
100% N=126 
 
 
In this study, majority of the patients had gastro intestinal cancer 
49(38.88%), 42(33.33%) had breast cancer, 20 (15.87%) had lung cancer, 
8 (6.34%) had multiple myeloma, 3 (2.38%) had hepato-cellular 
carcinoma, 2 (1.58%) had bone cancer and   1 (0.79%) had kidney and 
prostate cancer. 
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GRAPHICAL REPRESENTATION OF PRIMARY TUMOUR 
SITE 
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7) DISTRIBUTION OF CANCER STAGES OF PATIENTS: 
 
TABLE NO:7 
 
PERCENTAGE FREQUENCY STAGE 
13.49% 17 0 
17.46% 22 1 
38.09% 48 2 
18.25% 23 3 
12.69% 16 4 
     
  Majority of the patients 87 (69.05%) had early stages of cancer- STAGE 0  to 
STAGE II. The remaining 39 (30.95%) had late stages of cancer. STAGE 0 cancer 
refers to patients with carcinoma in-situ. 
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BAR GRAPH SHOWING DISTRIBUTION OF CANCER STAGES 
OF PATIENTS: 
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8) ORAL ANTICANCER DRUGS PRESCRIBED: 
 
The different oral anticancer drugs prescribed are: 
 
 
TABLE NO: 8 
Percentage Frequency(n) Drugs 
38..88% 49 Capecitabine 
30.95% 39 Tamoxifen 
6.34% 8 
Aromatase 
inhibitors 
8.73% 11 Gefitinib 
2.38% 3 Imatinib 
1.58% 2 Temozolomide 
1.58% 2 Bicalutamide 
2.38% 3 Etoposide 
1.58% 2 Methotrexate 
1.58% 2 Sorafenib 
3.96% 5 Thalidomide 
 
N=126 
 
 
The drugs  involved were  Capecitabine 49(38.88%), tamoxifen 39(30.95%),  
gefitinib 11(8.73%), aromatase inhibitors 8(6.34%), thalidomide 5(3.96%), imatinib, 
etoposide 3(2.38%), temozolomide, bicalutamide, methotrexate,  sorafenib 2(1.58%). 
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GRAPHICAL REPRESENTATION OF DISTRIBUTION ORAL 
ANTICANCER DRUGS PRESCRIBED: 
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9) ADHERENCE: 
 
  The majority of the patients 113(89.68%) reported no difficulties in adherence 
to their oral anticancer treatment regimen, 10(7.93%) of the total population were 
medium adherent and 3(2.38%) of the patients were poorly adherent to their oral 
anticancer regimen. 
 
Percentage Frequency(n) Adherence 
89.68% 113 High 
7.93% 10 Medium 
2.38% 3 Poor 
100% N=126 
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GRAPHICAL REPRESENTATION SHOWING ADHERENCE IN 
PATIENTS: 
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10)  RESPONSE OF PATIENTS ON MISSED DOSE OF ORAL 
ANTICANCER: 
 
TABLE NO:10 
 
Percentage 
 
Frequency(n) 
 
Action taken 
 
12.7% 
 
16 
 
Skip missed doses 
77.77% 98 
Resume taking the 
dose when 
remember 
 
3.17% 
4 
Double up with 
next dose 
 
4.76% 
 
6 
 
Do not know 
1.58% 2 Contact physician 
100% n=126 
 
 
When asked what they would do if they missed a dose of their oral anticancer 
medicine, a variety of responses were given. Majority of the patients 98(77.77%) 
resume taking their doses when remember, 16(12.7%) patients skipped their missed 
doses, 6(4.76%) patients don't know what to do if a dose is missed,  4(3.17%) taken 
up their medication with their next dose, that is double up with next dose and 
2(1.58%) patients were contact physician when missed a dose. 
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GRAPHICAL REPRESENTATION OF VARIOUS RESPONSE OF 
PATIENTS ON THEIR MISSED DOSE OF ORAL ANTICANCER 
DRUGS: 
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11)  COURSE OF ACTION TAKEN BY PATIENTS IF A DOSE IS 
DROPPED ON THE FLOOR: 
 
TABLE NO: 11 
 
 
Percentage 
 
Frequency(n) 
 
Action taken 
 
78.57% 
 
99 
 
Consume 
 
11.9% 
 
15 
 
Throw 
 
9.52% 
 
12 
 
Never dropped 
before 
 
100% 
 
N=126  
 
When asked how patients would treat their oral anticancer drugs that are 
dropped on the floor, the majority of the patients 99(78.57%) would pick up their 
medication with their medication with their fingers and consume. Only 
15(11.9%)would throw their dropped medication into the bin regardless of location 
and 12(9.52%) insisted that they have never dropped their medication before and 
would therefore not want to consider the hypothetical situation. 
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GRAPHICAL REPRESENTATION SHOWING THE COURSE OF 
ACTION TAKEN BY THE PATIENTS WHEN ONE DOSE IS 
MISSED: 
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12) ACTION TAKEN, AFTER HANDLING THE ORAL 
ANTICANCER AGENTS: 
 
TABLE NO: 12 
 
Percentage Frequency(n) Action taken 
10.31% 13 Wash hands 
89.69% 113 
Do not wash 
hands 
0% 0 
Wear gloves 
while taking 
          
All the patients interviewed, indicated that they would not wear gloves when 
handling their oral anticancer agents. Majority of the patients 113(89.69%) responded 
that they do not wash their hands after handling their oral chemotherapeutic agents. 
Only 13(10.31%) would wash their hands. No one claimed that they would use 
alcohol or other agents to wipe their hands instead of washing. 
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GRAPHICAL REPRESENTATION OF COURSE ACTION BY 
THE PATIENTS AFTER HANDLING THE ORAL 
CHEMOTHERAPEUTIC AGENTS: 
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13)  STORAGE: 
 
TABLE NO:13 
 
Percentage Frequency(n) Storage 
46.82% 59 Place separately 
53.17% 67 
Place with other 
drugs 
100% N=126 
 
          
More than half, 67(53.17%) claimed that they would store their oral anticancer 
agents with other drugs. Rest of the patients store their anticancer drugs separately 
from other medications. 
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GRAPHICAL REPRESENTATION SHOWING THE STORAGE 
OF ORAL ANTICANCER AGENTS: 
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14) RESPONSE TO POST DOSE VOMITING: 
Table no:14 
  
Percentage Frequency(n) Action taken 
3.96% 5 
Take another dose 
immediately 
11.11% 14 
Take another dose 
after sometimes 
5.55% 7 Miss that dose 
1.58% 2 Consult the doctor 
77.77% 98 Never happened 
100% N=126 
 
 
 
    When asked how the patients would response to the post dose vomiting condition, 
98(77.77%) had never happened the situation. 14(11.11%) take another dose after 
sometimes, 7( 5.55%)miss that dose and 5(3.96%) take another dose immediately 
after vomiting. Only 2(1.58%) consult the doctor for further clarification. 
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GRAPHICAL REPRESENTATION SHOWING THE RESPONSE 
TO POST DOSE VOMITING: 
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15) HANDLING OF LEFTOVER MEDICATION: 
 
Table no:15 
 
PERCENTAGE FREQUENCY(n) ACTION TAKEN 
23.01% 29 
Would continue with 
their medication 
20.63% 26 
Would continue in the 
rest period of cycle 
51.58% 65 Never had extras before 
4.76% 6 
Show the extra 
medication to 
doctors/pharmacists 
100% n=126 
 
    
 
 When asked what they would do with leftover medication before the next 
appointment or refill, more than half 65(51.58%) never had extras before and 
29(23.01%) would continue their medication, 26(20.63%) claimed that they would 
continue in the rest period of the cycle. Only 6(4.76%) indicated that they would tell 
or show the extra medication to their doctors or pharmacists. 
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GRAPHICAL REPRESENTATION SHOWINGHANDLING OF 
LEFTOVER MEDICATION: 
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16)  ADHERENCE (HIGH) ON DIFFERENT ANTICANCER 
DRUGS: 
TABLE NO:16 
percentage Frequency(n)       Drugs  
91.83% 45/49 Capecitabine  
87.18% 34/39 Tamoxifen  
100% 5/5 Aromatase 
inhibitors  
90.90% 10/11 Gefitinib  
100% 3/3 Imatinib  
100% 2/2 Temozolomide  
100% 2/2 Bicalutamide  
66.66% 2/3 Etoposide  
100% 2/2 Methotrexate  
100% 2/2 Sorafenib  
75% 6/8 Thalidomide  
 
Majority of the patients were on capecitabine and the adherence rate was 
found to be 45 of 49(91.83%), in case of tamoxifen the adherence was 34 of 
39(87.18%). Adherence in case of gefitinib is 10 of 11(90.9%), etoposide 2 of 
3(66.66%), thalidomide 6 of 8(75%). Aromatase inhibitor, imatinib, temozolomide, 
bicalutamide, methotrexate and sorafenib have 100% of adherence because only less 
number(5 or less than 5) of the patients were on these tablets. 
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GRAPHICAL REPRESENTATION OF ADHERENCE (HIGH) ON 
DIFFERENT ANTICANCER AGENTS: 
 
 
  
PATIENTS' DEMOGRAPHICS: 
Among 126 subjects, majority are female patients 70(55.55%) and 56(44.44%) 
male patients. More than half 111(88.09%) having only secondary school education 
or less. 35(27.7%) of patients were alcoholics, 21(16.66%) were smokers and 
4(3.17%) of patients were tobacco users. The mean age of the patients were about 60 
years old and the majority of the patients falling in the range of 45-74 years old. 
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DOSING AND COMPLIANCE: 
 
 Most of the patients administered their own oral anticancer agent and only few 
were  administered by the caregiver. The majority of the patients 113(89.68%) 
expressed that their treatment regimens were simple to adhere , 10(7.93%) of the 
patients were medium adherent and 3(2.38%) of the patients were poorly adherent to 
their oral anticancer regimen. The majority of the drugs prescribed were Capecitabine 
49(38.88%), tamoxifen 39(30.95%), gefitinib 11(8.73%), aromatase inhibitors 
8(6.34%), thalidomide 5(3.96%), imatinib, etoposide 3(2.38%) and temozolomide, 
bicalutamide, methotrexate and sorafenib 2(1.58%). 
 
STORAGE AND HANDLING: 
 
 More than half of the total population, 67(53.17%) claimed that they would 
store the oral anticancer agents with the other drugs. Hand washing habit after 
handling the oral anticancer agents was not a common habit reported by studied 
subjects. Only 13(10.31%) claimed that they habitually wash their hands after 
handling oral anticancer drugs. Only 15(11.9%) patients would throw their dropped 
medication into the bin. Most of the patients 99(78.5%) would pick up their 
medication with their fingers and consume, though 12(9.52) insisted that they have 
never dropped their medication before. Majority of the patients 98(77.77%) resume 
taking their doses when remember, if they missed one dose of oral anticancer 
medication, 16(12.7%) skipped the missed dose and 4(3.17%) double up with the next 
dose. 
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SUGGESTION: 
Patient Education & Information for safe handling of oral anticancer 
agents: 
 
 Before every treatment cycle, all patients should be seen by a specialist 
pharmacist or nurse. The pharmacist/technician handing the drugs to the 
patient (or relative or carer) must ensure that they fully understand :-  
 How and when to take their medicines. Some patients may find it particularly 
hard to remember the idea of repeated short courses of treatment with 'gaps' 
between them  
 What to do in the event of missing one or more doses  
 What to do in case of vomiting after taking a dose  
 Likely adverse effects and what to do about them  
 Principles of safe handling, storage and disposal  
 That if used, medicine spoons or measures should be disposable and used once 
only.  
 Arrangements for monitoring  
 Contact details for specialist advice  
 Keep the medication in the container in which it was supplied with the 
dispensing labels.  
 Patients should receive verbal and written information about their oral 
anticancer medication from the initiating hospital, including details of the 
intended regimen and treatment plan, taken from the original protocol. 
 
INFORMATION FOR PATIENTS (COUNSELLING POINTS):  
 
 Missed dose: If you forget one dose, do not take a double dose in one day to 
make up for a missed dose. If remember 30 to 90 minutes after they should 
have taken their tablets, then take the missed dose; if it is near to the time 
when their next dose is due, do not take missed dose. Inform doctor/ 
chemotherapy unit and keep to normal dosing schedule.  
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 Post dose vomiting: Do not take an extra capsule without consulting your 
doctor. Anti-emetics should be given before and during therapy to reduce 
nausea and vomiting. 
 
 Disposal of medication: If your doctor decides to stop the treatment, return 
any remaining tablets to the pharmacist to be disposed of in a manner 
appropriate for disposal of cytotoxic & cytostatic medicines.  
 
 Advice for patients:  
 Capsules should be swallowed whole, not chewed.  
 Patients should not breast feed whilst taking oral anticancer agents 
 Tablets should not be divided. There is no risk in handling tablets 
provided outer coating on the tablets is intact. 
 Most of the tablets are provided with the outer coating which  is 
intact, there is no risk in handling.  
 Do not open blister if there is evidence of capsule leakage. Urine 
and faeces produced for up to 4 and 7 days, respectively after a 
dose should be handled wearing protective clothing. 
 The contents of capsules should not be inhaled or allowed to come 
into contact with the skin or mucous membranes.  
 If accidental contact with powder from capsule into the eye, skin or 
mucosa, immediately rise with water and seek medical attention. 
 Intact capsules should be swallowed whole with water, not sucked, 
bitten or chewed.  
  Do not break or chew the capsules. 
  Wash hands immediately after handling/halving tablets, avoid 
contact with eyes and inhalation of particles. 
 Use of protective gloves to dispense oral hazardous drugs is 
recommended.  
  Hands must be washed thoroughly after each dispensing  
 Urine and faeces produced for up to 48 hours and 5 days, 
respectively after a dose should be handled wearing protective 
clothing. 
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Dos for Oral Chemotherapy Don'ts for Oral Chemotherapy 
On receiving your prescription, review 
the package label, specifically checking 
medication name and dosage.  
Leave medication in open areas, near 
sources of water, direct sunlight, or where 
they can be accessed by children or pets.  
Ensure that you completely understand 
when and how to take the medication 
and ask questions if there is any 
confusion.  
Store medications in the areas where food 
or drinks are stored or consumed.  
Transport and store medicine as 
instructed and as outlined in the 
packaging label.  
Crush, break, or chew tablets.  
Use gloves if possible and wash hands 
thoroughly before and after glove 
application. If gloves are not worn, tip 
tablets and capsules from their 
container/blister pack directly into a 
disposable medicine cup.  
Double-up on doses, unless instructed by 
a health care professional.  
Administer the medication as 
instructed.  
Share prescriptions or medication.  
Keep a journal of adverse effects. 
Make a list of adverse effects for which 
the health care professional has to be 
contacted immediately.  
Assume that oral chemotherapy is safer 
than intravenous chemotherapy.  
Consider using adherence devices. Use 
separate devices for cytotoxic and 
noncytotoxic agents.  
Skip doses unless instructed by your 
physician.  
Report any overdosing immediately.  Discard medication down the toilet or in 
the garbage.  
 Keep information ready for necessary 
action in the event of accidental exposure 
(including emesis and accidental 
ingestion). 
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 Return wet, damaged, unused, 
discontinued, or expired medications to 
the pharmacist or hospital for disposal.  
 Report all medications (prescription and 
nonprescription as well as 
complementary and alternative 
medicines) and any specific dietary 
requirements to the health care 
provider/prescriber, at the time of 
assessment and consultation. Inform 
other health care professionals that you 
are on oral chemotherapy (eg, surgeons 
and dentists).  
 Minimize the number of individuals 
coming in contact with the cytotoxic 
medications.  
 Wash the patient's clothes and bed linen 
separately from other items.  
 
It is recommended that caregivers wear gloves at all times while handling 
oral chemotherapeutic agents as well as contaminated items in order to minimize 
risk of exposure. 
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Oral agents are expected  to represent up to 25% of all drug used  for 
treatment of cancer  in the  upcoming  decade.  As oral anti cancer agents are  gaining  
much popularity worldwide, this study is timely because it has highlighted numerous 
aspects regarding oral anticancer drugs. In this study the majority of the patients had 
received only one oral drug, they are usually given along with parenteral agents. In 
this study over 89.68% of the surveyed patients claimed that they are adherent with 
their oral anti canc er drugs. In an article written by O’Neill et al., the authors stated 
that there was a tendency for reductions in compliance among cancer patients during 
chronic treatment.  However this study was not designed to study adherence over  
long- term use. Multiple strategies are available to  access patients’ adherence to 
medications, but none of this strategies is considered to be the golden standard. In this 
study, patient questionnaires were administered to access patients’ adherence to oral 
anti cancer drugs. This method is regarded to be the simplest method in the clinical 
setting. 
 
 
Evidently there is a need to educate patients on the importance to handle oral 
anti cancer drugs appropriately. .Patients generally seemed have no problems with 
understanding and  adhering  to  their anticancer treatment regimen. However,  their  
varied  responses to a missed dose suggest that patients are too complacent with their 
medication habits . Patients handling practices with their oral anti cancer agents also 
showed their lack of knowledge in this area as well as lack of understanding about the 
nature of the medicine.  The oral anti cancer agents were regarded patients as any 
other ordinary medicine as shown when more than half (78.57%) would pick up and 
consume their dropped medication. Most patients admitted that  hand washing after 
handling oral anti cancer drugs was not their routine practice; hand washing and  
appropriate gloving are recommended when handling oral cytotoxics such as 
etoposide.  There  is  no  clear   guideline  for  handling  a  number  of  agents,  for  
example, imatininib, gefitinib, erlotinib, and others of similar pharmacological 
classes. It would appear prudent to adopt these practices, but the literature for health 
professionals as well as patients has been inconclusive. O ne limitation of this study is 
the lack of assessment of health care professionals’ perceptions of oral anticancer 
drugs.  Health care professionals’  views  are important as many institutions are 
developing standard policies to strengthen patient education about safe hand ling of 
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oral anticancer drugs. In order to ensure quality education programs can be designed 
to  improve  patients’ understanding as well as safe use of oral anticancer agents, 
health care professionals should also  have a good understanding on safe handling of 
oral anticancer agents. Availability of oral anticancer agents with novel mechanisms 
of action has brought new hopes to the treatment of cancer. However, new issues rise 
simultaneously and these issues require attention. Healthcare professionals, including 
oncologists, oncology nurses,  as  well  as  oncology  pharmacists  must  play  active  
roles  to  facilitate  patients  in assuming more responsibility to manage their oral 
anticancer drugs. Improved communication may assist to improve patients’ treatment 
outcomes and to prevent detrimental events. 
 
 
 
 
 
 
 
 
 
 
conclusion 
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Patients clearly need to be educated about the nature of their medications, 
particularly on how they should handle and their practices with their medication 
appropriately. Though all patients are educated on how to take their oral anti-cancer 
agents and the course of action in the event of a missed dose, more can definitely be 
done to reinforce their knowledge. The majority of patients receiving oral anticancer 
agents reported no  difficulty  in adhering to  their oral anticancer regimens as 
prescribed. However, this study demonstrated the need to improve patients’ 
understanding of the requirements for storage, handling, and safe administration of 
oral anti cancer drugs. 
 
 
Healthcare   professionals could also play a more active role in educating their 
patients to  allow  patients  to  assume  appropriate  responsibility  in  managing  their  
condition  and medication. 
 
 
summary  
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Among various diseases, cancer has become a big threat to human beings 
globally. As per Indian population census data, the rate of mortality due to cancer in 
India was high and alarming with about 806000 existing cases by the end of the last 
century. Cancer is the second most common disease in India responsible  for 
maximum mortality with about 0.3  million deaths per year. This is owing to the poor 
availability of prevention, diagnosis and treatment of the disease. All types of cancers 
have bee n reported  in Indian population including the cancers of skin,  lungs, breast, 
rectum, stomach, prostate,  liver, cervix, esophagus,  bladder, blood,  mouth etc.  The 
causes of such high  incidence rates of these cancers  may be both internal (genetic, 
mutations, hormonal, poor immune conditions) and external or environmental factors 
(food habits, industrialization, over growth of population, social etc.). 
 
Over the past decade, there is an observed paradigm shift in cancer treatment, 
moving from parenteral to oral anticancer drug administration as a number of oral 
anticancer agents are  now  widely used  worldwide. In  comparison  to  intravenous  
anticancer  treatments, administration of anticancer therapy orally  is appealing 
because it offers great convenience and  flexibility in terms of timing and  location of 
drug ad ministration.  However, this also implies that patients must assume greater 
responsibilities for their treatment,  with regards to adherence and safe handling of 
their oral anticancer drugs. 
 
With the rise  in availability and  increasing use of oral anticancer agents, 
concerns about adherence to prescribed regimens will become an increasingly 
important issue in oncology. In view of an increased usage of oral anticancer drugs in 
the contemporar y treatment of cancer this study aimed to  measure the adherence of 
oral anticancer drugs and patients behavior regarding storage and handling of oral anti 
cancer drugs. 
 
This was a single centre, cross sectional, interviewer administered study 
carried out by applying a structured interview to cancer patients who were on oral anti 
cancer medication. For checking the adherence Morisky’s 8-item questionnaire were 
used, the adherence was measured by giving score to each question, if the score is 0, 
cons idered as high adherent, 1 or 2 average adherence and >2 poor adherence. In this 
summary  
ULTRA COLLEGE OF PHARMACY, MADURAI Page 76 
study, more than half of the patients (89.68%)  responded   high  adherence. In this 
study  the  majority  of  the  patients  were gastrointestinal cancer patients (38.88 %), 
and breas t cancer (33.33 %). The adherence rates in different  drug were found  to  be  
as,  capecitabine  (91.83%),  tamoxifen  (87.18%),  gefitinib 
(90.9%) and thalidomide (75%). 
 
Hand washing after handling oral anticancer agents was not a common habit 
reported by  study  subjects,  only  13  (10.31%)  claimed  that they  habitually  wash  
their  hands  after handling oral anticancer  drugs. When asked  how patients would 
treat their oral anticancer drugs that are dropped on the floor, 99 (78.57 %) indicated 
that they would picked up and consume it, 15 (11.9 %) would refuse to take and 
dispose  it immediately. However, when asked what they would do if they a missed a 
dose of their anticancer medicine, a variety of responses were given. Majority of the 
patients 98 (77.77%) resume taking the doses when remember, 16 (12.7%) skipped 
their doses and 4 (3.17 %) double up their doses with next dose. 
 
It may be concluded that the study “patients’ adherence, practices and 
behavior regarding the oral anticancer  drugs”  was  found  to be effective in  
monitoring adherence, behavior regarding handling and storage of their oral 
anticancer medication. 
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